# A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

> **NCT01618708** · NA · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 357 (actual)

## Conditions studied

- Osteoarthritis, Hip

## Interventions

- **DEVICE:** Synvisc-One (hylan G-F 20)
- **DEVICE:** Placebo

## Key facts

- **NCT ID:** NCT01618708
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2016-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01618708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01618708, "A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01618708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*